Is Vorinostat covered by medical insurance?

The histone deacetylase inhibitor Vorinostat was approved by the U.S. Food and Drug Administration in October 2006 for the treatment of cutaneous manifestations of cutaneous T-cell lymphoma in patients with progressive, persistent, or relapsing disease on or after two systemic therapies. Pooled vorinostat clinical trial data from 498 patients with solid or hematologic malignancies showed that vorinostat was well tolerated as monotherapy or in combination.

Vorinostatt1/2 is approximately 60 to 100 minutes. There are no significant differences in the absorption and bioavailability of vorinostat with or without food, although taking vorinostat with food may prevent some gastrointestinal side effects. Vorinostat is not metabolized by or inhibits the cytochrome P-450 isoenzyme system, and only two drugs (warfarin and sodium valproate) interact with vorinostat. The most commonly reported drug-related adverse events associated with monotherapy were fatigue, nausea, diarrhea, anorexia, and vomiting. Grade 3/4 drug-related adverse events included fatigue, thrombocytopenia, dehydration, and decreased platelet count. The most common drug-related adverse events observed with vorinostat in combination therapy were nausea, diarrhea, fatigue, vomiting, and anorexia.

The original drug of vorinostat is not currently on the market in China, and therefore cannot be included in the national medical insurance coverage. Overseas, there is an American version of the original drug, specifications100mg*120 pills per box, which may cost around 100,000 yuan (the price may fluctuate due to exchange rate effects). It is very expensive, and there is currently no generic version of vorinostat produced and launched. For more drug information and specific prices, please consult a medical consultant.